- ArriVent BioPharma, Inc. press release (NASDAQ:AVBP): FY net loss was $69.3 million.
- Research and development expenses were $64.9 million.
- General and administrative expenses were $9.7 million.
- As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $150.4 million.
More on ArriVent BioPharma
- ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
- ArriVent Biopharma Seeks $100 Million IPO For Lung Cancer Drug
- ArriVent BioPharma upsizes proposed IPO to $150M from $100M
- ArriVent, lung cancer drug developer, files for $100M IPO
- Historical earnings data for ArriVent BioPharma, Inc.